A psychedelic coach and a therapist are not two names for the same job. A therapist is a licensed healthcare professional who can assess and treat mental health conditions within a regulated legal framework. A psychedelic coach is an educator and non-clinical support person who works with preparation, harm reduction, meaning-making and behaviour change, and who is legally not permitted to diagnose or treat anything. If you are choosing support around an altered-state experience, the practical question is not which title sounds more serious. It is whether your situation is a clinical one.
This article explains the boundary, why it gets blurred, and how to decide which kind of support fits your case.
Key takeaways
- A therapist or clinical psychologist holds a regulated, protected healthcare title in most European countries. A coach does not.
- Only a licensed clinician can diagnose, treat a mental health disorder, or manage medication questions.
- A coach can work on preparation, safety literacy, reflection, values, habits and follow-through. That is a real scope, not a lesser version of therapy.
- Psychedelic-assisted therapy as studied in trials is not what most people buy on the open market. Trial protocols include screening, medical supervision, structured psychological support and follow-up.
- The support component in clinical trials is inconsistently reported and poorly standardised, so we do what the studies do is usually an overclaim.
- Serious adverse events in trials were reported for roughly 4 percent of participants with pre-existing neuropsychiatric conditions, so screening is not a formality.
- If you have symptoms that meet the threshold of a disorder, you need a clinician. A coach can work alongside that, not instead of it.
Definitions: what each role legally is
Therapist, clinical psychologist or psychotherapist. In Spain, psychology in the health sector is a regulated profession. Ley 33/2011 (Ley General de Salud Publica) created the regulated healthcare profession of Psicologo General Sanitario, and Ley 44/2003 governs the ordering of healthcare professions including the specialist title in clinical psychology. Practising requires the official qualification and registration with a professional college. Requirements differ across Europe, and in some jurisdictions the word therapist on its own is not protected even where psychologist is. Date and check this locally before you assume anything.
Psychiatrist. A medical doctor. Prescribes, manages medication, assesses risk, handles psychiatric emergencies. The only role in this list that can answer the question of whether a given drug interaction is safe for you.
Psychedelic coach. A non-clinical practitioner offering education, preparation and integration support. The International Coaching Federation defines coaching as partnering with clients in a thought-provoking and creative process that inspires them to maximize their personal and professional potential. Coaching is not a regulated healthcare profession in the EU. There is no protected title of psychedelic coach anywhere in Europe that I am aware of as of September 2026, which is exactly why credentials, supervision and stated scope matter so much.
Facilitator, sitter or guide. Someone present during an experience. This is a different function again, and in most of Europe involvement with controlled substances carries legal exposure. I do not provide substances and I do not sit sessions.
Integration. The first extensive concept analysis of the term, by Bathje and colleagues in 2022, found that integration is offered by therapists, coaches and other practitioners, that definitions vary widely, and that this variety has produced real confusion about what integration even is. If a practitioner uses the word without defining it, ask them to.
Psychedelic coach vs therapist: the core differences
The honest summary: a coach works with a functioning system that wants to change direction. A clinician works with a system that is unwell. Those overlap in real life, which is why good practitioners of both kinds refer.
Why the line gets blurred
Three things create the confusion.
First, the phrase psychedelic-assisted therapy is used loosely. In trials it means something specific. In the Goodwin 2022 psilocybin trial for treatment-resistant depression, participants had preparatory sessions before dosing and multiple integration visits afterwards, with psychological support scheduled at study visits, inside a medically supervised protocol with screening and follow-up. A weekend retreat plus two calls is not that, even if the marketing uses the same words.
Second, the therapy part of psychedelic trials is genuinely under-specified. Brennan, Kelman and Belser reviewed reporting practices across psychedelic clinical trials and found that psychological support, therapy and psychosocial interventions are described inconsistently and often thinly. So when a practitioner says their method is evidence-based because of the trials, the accurate response is that the drug arm has evidence and the support arm is much less well characterised.
Third, coaching has no gatekeeper. Anyone can print a business card. That is not an argument against coaching. It is an argument for asking harder questions before you pay anyone.
Evidence and limitations: what we can and cannot claim
The strongest psychedelic evidence comes from randomised controlled trials in screened clinical populations, not from retreats, ceremonies or coaching practices. Three limits are worth holding onto.
Population
Trial participants are heavily screened. People with personal or family histories of psychosis, schizophrenia or bipolar disorder are typically excluded, along with significant cardiac risk and various medication profiles. Results from that population do not transfer automatically to the general public.
Setting
Trials happen with medical backup, structured preparation, and defined follow-up. Hinkle and colleagues (2024, JAMA Psychiatry) reviewed adverse events across 214 studies of classic psychedelics, with analysable adverse event data from 114 studies covering 3,504 participants. Serious adverse events were reported in no healthy participants but in roughly 4 percent of participants with pre-existing neuropsychiatric disorders, including worsening depression, suicidal behaviour, psychosis and convulsive episodes. That is in the safest available context.
Design
These are associations inside controlled protocols, not proof that a given intervention will help a given person outside one. Functional unblinding (participants correctly guessing whether they received the active drug) is a known problem in this literature and was among the concerns raised in the US regulatory process for MDMA-assisted therapy, which received a Complete Response Letter in August 2024 rather than approval.
On the risk side, non-clinical settings have their own signal. Evans and colleagues (2023) surveyed 608 people reporting extended difficulties after psychedelic use. The most common were anxiety and fear, existential struggle, social disconnection, depersonalisation and derealisation. For roughly a third of that sample, difficulties persisted more than a year. This is a self-selected sample of people who had problems, so it cannot tell you how common such difficulties are. It does tell you what they look like when they happen, and that they are not always brief.
There is also a harms question inside the professional relationship itself. McNamee, Devenot and Buisson argued in JAMA Psychiatry (2023) that harms in psychedelic-assisted therapy have been under-studied, pointing to increased suggestibility, vulnerability to abuse and overdependency on the practitioner. Heightened suggestibility is a feature of these states. That is precisely why role clarity, boundaries and a complaints route are safety issues, not paperwork.
As of September 2026, the European Medicines Agency has not approved a psychedelic medicine for general therapeutic use. The EMA held a multi-stakeholder workshop in April 2024 towards an EU regulatory framework, and its stated position was that development programmes must fit existing regulatory frameworks. Anyone telling you otherwise is selling something.
A decision framework: which support do you actually need
Work through this honestly. Answer yes to anything in Column A and the clinical route comes first.
Column A: start with a licensed clinician
- You have a current diagnosis, or you suspect one and have never been assessed.
- You have a personal or family history of psychosis, schizophrenia or bipolar disorder.
- You are taking psychiatric medication, including SSRIs, lithium, MAOIs or mood stabilisers.
- You have had thoughts of harming yourself, recently or in the past year.
- You have a significant cardiac condition, uncontrolled hypertension, or you are pregnant.
- You are in acute crisis, or you have been in one within the last few months.
- You had an experience that left you dissociated, unable to work, or unable to sleep for more than a couple of weeks.
Column B: coaching is a reasonable fit
- You are functioning: working, sleeping, eating, connected to people.
- You have already had an experience and want structured reflection rather than treatment.
- You want to understand risk and preparation before making any decision.
- Your problem is follow-through: you saw something clearly and nothing in your life changed.
- You want someone to help you turn insight into a behavioural system.
- You want education and honest information, not a promise.
Column C: both, in parallel
- You are in therapy and want practical help with preparation, structure and habits.
- Your clinician is not familiar with this territory and you want a second, non-clinical perspective that stays in its lane.
Parallel support only works when the coach knows about the clinical work and defers to it. If a coach discourages you from telling your therapist, that is a red flag, full stop.
Questions to ask any practitioner before you pay
- What exactly are you licensed or certified to do, and by whom?
- What are you not qualified to do, and what happens when we hit that boundary?
- Who do you refer to, and have you actually referred anyone in the last year?
- Do you have clinical supervision or peer supervision? How often?
- What is your written scope of practice, and can I see it?
- What is your policy if I disclose suicidal thoughts?
- Do you provide, source or recommend substances? (The correct answer in Europe is no.)
- What outcome are you promising? (The correct answer is none.)
A practitioner who cannot name their own limits has not thought about them.
Risks, boundaries, and when to seek professional care
Coaching cannot substitute for clinical care, and the people most likely to be harmed by that substitution are the ones least equipped to notice it happening. If you are unwell, a warm, articulate, non-clinical practitioner can feel like enough. It is not.
Seek licensed medical or psychiatric help promptly if you experience: hearing or seeing things others do not, persistent beliefs others find alarming, inability to sleep for several nights, sustained dissociation or derealisation, inability to carry out basic daily function, or any thought of harming yourself or someone else. Use your local emergency number or your country's official mental health services. In Spain, that means your GP, your regional health service, or emergency services. Do not wait for a coaching call.
Psychedelics remain controlled substances across most of Europe, with laws varying by country and changing over time. Nothing here encourages illegal activity. Screening is not a formality, and no practitioner of any kind can make a substance safe for someone it is contraindicated for.
FAQ
Can a psychedelic coach diagnose me?
No. Diagnosis is a clinical act reserved for licensed professionals. If a coach offers you a diagnosis, they are operating outside their scope, and you should treat that as disqualifying.
Is coaching just cheaper therapy?
No. It is a different function. Coaching works forward from a stable baseline: goals, meaning, structure, behaviour. Therapy works with symptoms, history and clinical formulation. If you need the second and buy the first because it costs less, you have not saved money.
My therapist does not know anything about psychedelics. What now?
That is common and it is not a reason to leave therapy. You can keep clinical care where it belongs and add non-clinical education separately, with both parties informed. Ask your therapist directly whether they are comfortable with you working on this in parallel.
Do I need a coach at all if I have already had the experience?
Not necessarily. Many people integrate well with friends, journalling, a stable routine and time. Support becomes more useful when insight is not translating into changed behaviour, or when the experience left something unresolved that keeps coming back.
Is certified psychedelic coach a real credential?
It reflects completion of a private training programme, not a licence. Private certification tells you someone did structured training and agreed to an ethical code. It does not carry the legal weight of a healthcare licence, and any honest coach will say so. The ICF Code of Ethics requires practitioners to identify their qualifications accurately and to refer clients on when coaching is not the right resource.
Can a coach help me decide whether to do this at all?
A coach can help you think it through, understand risk categories, and identify what you would need to rule out with a doctor first. A coach cannot tell you it is safe for you. Nobody can do that from outside your medical record.
Where to start
If you are trying to work out which category you are in, start with the free safety self-assessment at https://entheogen.expert/safety. It walks you through the contraindication questions a responsible practitioner would ask in a first conversation, and it will tell you plainly when the answer is to speak to a doctor first. If afterwards you want to talk about non-clinical preparation or integration support, you can look at what I offer at https://entheogen.expert/services.
About the author and reviewer
Author and reviewer: Vladislav Andreev. Certified Psychedelic Coach (Psychedelic Coaching Institute), harm-reduction educator and mental health educator based in Barcelona, working in English and Russian. I am not a doctor, psychiatrist, psychologist or psychotherapist. I do not diagnose, treat, prescribe, provide substances or sit sessions. I work in education and coaching only, and I refer to licensed clinicians when a situation calls for one. More on my background and why I do this work: https://entheogen.expert/my-story
This article was reviewed for scope, accuracy and non-clinical boundaries by the author. It has not been reviewed by a licensed clinician or by a Spanish lawyer.
References
[1] Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology. 2022;13:824077. doi:10.3389/fpsyg.2022.824077 (Verified.)
[2] Goodwin GM, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. 2022. doi:10.1056/NEJMoa2206443 (Verified. Volume and page numbers not independently confirmed and therefore omitted.)
[3] Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. doi:10.1001/jamapsychiatry.2024.2546 (Verified.)
[4] Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLOS ONE. 2023;18(10):e0293349. doi:10.1371/journal.pone.0293349 (Verified.)
[5] Brennan W, Kelman AR, Belser AB. A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. Psychedelic Medicine. 2023;1(4):218-229. doi:10.1089/psymed.2023.0007 (Verified.)
[6] McNamee S, Devenot N, Buisson M. Studying Harms Is Key to Improving Psychedelic-Assisted Therapy: Participants Call for Changes to Research Landscape. JAMA Psychiatry. 2023;80(5):411-412. https://pubmed.ncbi.nlm.nih.gov/36988924/ (Citation verified. DOI not independently confirmed and therefore omitted.)
[7] International Coaching Federation. ICF Code of Ethics (rev. 25 June 2021). https://coachingfederation.org/wp-content/uploads/2021/01/ICF-Code-of-Ethics-1.pdf (Verified, full text read.)
[8] European Medicines Agency. Report: EMA multi-stakeholder workshop on psychedelics (16-17 April 2024). https://www.ema.europa.eu/en/documents/report/report-ema-multi-stakeholder-workshop-psychedelics_en.pdf (Verified as an EMA-published document.)
[9] Ley 33/2011, de 4 de octubre, General de Salud Publica (Spain). Boletin Oficial del Estado. https://www.boe.es/diario_boe/txt.php?id=BOE-A-2011-15623 (Source verified. The specific provision creating the Psicologo General Sanitario profession requires confirmation by a Spanish lawyer before this statement is relied on legally.)
[10] Multidisciplinary Association for Psychedelic Studies. Statement on the FDA's public release of the Complete Response Letter for MDMA-assisted therapy. https://maps.org/2025/09/04/fda-public-release-of-crl/ (Secondary source. The primary FDA document should be cited if this claim is load-bearing.)
Last reviewed: 2 September 2026. Next review due: March 2027.
Educational content only. This is not medical advice, therapy, or a clinical diagnosis, and it does not encourage illegal activity. It exists to reduce risk for adults making their own decisions. Reviewed for scope by Vladislav Andreev, Certified Psychedelic Coach (Psychedelic Coaching Institute), harm-reduction educator, Barcelona.